{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:27:25Z","timestamp":1790893645766,"version":"4.1.0"},"reference-count":31,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T00:00:00Z","timestamp":1602201600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T00:00:00Z","timestamp":1602201600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["61771022"],"award-info":[{"award-number":["61771022"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Laboratory Analysis"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Enzyme\u2010linked immunosorbent assay (ELISA) has traditionally been used to detect myeloperoxidase (MPO) and proteinase 3 (PR3) antibodies, although it is time\u2010consuming and physically demanding. As a novel and highly effective immunoassay, we compared chemiluminescent immunoassay (CIA) with ELISA to verify the application value of CIA in MPO and PR3 antibodies detection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>By ELISA and CIA, serum levels of anti\u2010MPO and anti\u2010PR3 antibodies were measured in 63 anti\u2010neutrophil cytoplasmic antibody (ANCA)\u2010associated vasculitis (AAV) patients (AAV group), including 47 microscopic polyangiitis (MPA) patients and 16 granulomatosis with polyangiitis (GPA) patients, in addition, 68 patients in interference control group (IC group), 19 healthy subjects in healthy control group (HC group). We compared MPO and PR3 antibodies levels and positive rates measured by these two methods among groups. Relationship and coincidence rate between ELISA and CIA were investigated. Diagnostic values for clinical outcomes for MPO and PR3 antibodies were assessed by receiver operator characteristic (ROC) curve.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In AAV patients, when detecting anti\u2010MPO (\n                      <jats:italic>r<\/jats:italic>\n                      \u00a0=\u00a0.90) and anti\u2010PR3 (\n                      <jats:italic>r<\/jats:italic>\n                      \u00a0=\u00a0.81), CIA was highly correlated with ELISA, companying with highly total (88.89%, 92.06%, respectively) and positive coincidence rates (84.78%, 77.27%, respectively). In HC group, anti\u2010PR3 positive rate detected by both immunoassay were 0, anti\u2010MPO almost were 0, which without statistically significant difference (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a0.32). In IC group, the total (76.47%, 58.82, respectively) and positive coincidence rates (48.38%, 30.00%, respectively) of anti\u2010MPO and anti\u2010PR3 were the lowest, but the negative coincidence rates reached 100%. By CIA, similar to ELISA, the levels of anti\u2010MPO were significantly higher both in AAV patients (56.00; [4.40\u2010235.30]) and MPA patients (98.00; [27.90\u2010324.70]) compared with either IC group (3.20; [3.20\u201018.55) (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&lt;\u00a0.0001) or HC group (3.20; [3.20\u20103.20]) (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&lt;\u00a0.0001), yielded an area under curve (AUC) of 0.76 for AAV and 0.89 for MPA, the concentration of anti\u2010PR3 in GPA group (66.65; [24.43\u2010150.00]) was significantly higher than that in IC group (2.3; [2.3\u201010.95]) (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&lt;\u00a0.0001) and HC group (2.3; [2.3\u20102.3]) (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&lt;\u00a0.0001), with an AUC of 0.92.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Similar to ELISA, CIA was competent to detect MPO and PR3 antibodies in AAV patients and healthy population, thus distinguish AAV patients from IC group and HC group and effectively diagnose MPA and GPA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/jcla.23615","type":"journal-article","created":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T08:53:56Z","timestamp":1602233636000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The performance of the chemiluminescent immunoassay for measuring serum myeloperoxidase and proteinase 3 antibodies"],"prefix":"10.1002","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1255-0611","authenticated-orcid":false,"given":"Xiuzhu","family":"Hou","sequence":"first","affiliation":[{"name":"Department of laboratory medicine Peking University Third Hospital Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of laboratory medicine Peking University Third Hospital Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4407-455X","authenticated-orcid":false,"given":"Tiancheng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of laboratory medicine Peking University Third Hospital Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1879-5377","authenticated-orcid":false,"given":"Jiansuo","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of laboratory medicine Peking University Third Hospital Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyan","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of laboratory medicine Peking University Third Hospital Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,10,9]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1590\/1806-9282.62.05.434"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-016-0410-7"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2019.07.002"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1839-5"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-010-9373-x"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/antib8020031"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208073"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2014.78"},{"key":"e_1_2_8_10_1","first-page":"DC22","article-title":"Comparing assay performance of ELISA and chemiluminescence immunoassay in detecting antibodies to hepatitis B surface antigen","volume":"10","author":"Madiyal M","year":"2016","journal-title":"J ClinDiagn Res"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2016.05.013"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.talanta.2018.09.049"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2020.112829"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2017.02.006"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2012.01.004"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780370206"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.062711"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780330807"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.37715"},{"key":"e_1_2_8_20_1","unstructured":"CLSI.User verification of performance for precision and trueness; approved guideline seconded in EP15\u2010A2 Wayne PA USA;2004."},{"key":"e_1_2_8_21_1","unstructured":"CLSI.Evaluation of the linearity of quantitative measurement procedures: a statistical approach in approved guideline EP6\u2010A2 Wayne PA USA;2003."},{"key":"e_1_2_8_22_1","first-page":"615","article-title":"ANCA testing: the current stage and perspectives","volume":"17","author":"Csernok E","year":"2013","journal-title":"ClinExp Nephrol"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/185416"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2018.11.013"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-3400994"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1159\/000183754"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140941"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ensci.2016.10.001"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1669914"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1177\/2324709619843944"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0208974"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2012.108"}],"container-title":["Journal of Clinical Laboratory Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcla.23615","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jcla.23615","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcla.23615","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T12:59:59Z","timestamp":1776085199000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jcla.23615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,9]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1002\/jcla.23615"],"URL":"https:\/\/doi.org\/10.1002\/jcla.23615","archive":["Portico"],"relation":{},"ISSN":["0887-8013","1098-2825"],"issn-type":[{"value":"0887-8013","type":"print"},{"value":"1098-2825","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,9]]},"assertion":[{"value":"2020-07-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e23615"}}